Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,500 | 1 | 52.0% |
| Unspecified | $8,750 | 1 | 47.9% |
| Food and Beverage | $23.86 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $9,500 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $8,750 | 1 | $0 (2020) |
| AbbVie Inc. | $23.86 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $23.86 | 1 | AbbVie Inc. ($23.86) |
| 2021 | $9,500 | 1 | Merck Sharp & Dohme Corporation ($9,500) |
| 2020 | $8,750 | 1 | Novartis Pharmaceuticals Corporation ($8,750) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: FACIAL AESTHETICS | ||||||
| 03/03/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $9,500.00 | General |
| 05/18/2020 | Novartis Pharmaceuticals Corporation | TAFINLAR (Drug) | — | In-kind items and services | $8,750.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 687 | 1,051 | $212,785 | $52,770 |
| 2022 | 10 | 742 | 1,170 | $225,358 | $56,448 |
| 2021 | 8 | 589 | 995 | $184,717 | $48,873 |
| 2020 | 7 | 430 | 650 | $113,370 | $25,972 |
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 224 | 325 | $49,377 | $19,424 | 39.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 88 | 105 | $36,015 | $6,882 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 68 | 77 | $18,644 | $6,875 | 36.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 63 | 69 | $23,046 | $5,943 | 25.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 98 | 132 | $26,664 | $5,015 | 18.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $8,624 | $2,636 | 30.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $16,920 | $2,316 | 13.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $4,950 | $1,508 | 30.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 68 | 260 | $23,920 | $1,258 | 5.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 21 | 25 | $4,625 | $913.06 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 232 | 323 | $48,773 | $20,940 | 42.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 84 | 98 | $33,614 | $7,213 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 79 | $18,644 | $6,518 | 35.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 120 | 160 | $32,320 | $6,258 | 19.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 74 | 87 | $29,058 | $6,189 | 21.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 34 | 34 | $9,350 | $2,441 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $6,272 | $2,047 | 32.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 12 | 16 | $11,600 | $1,828 | 15.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 75 | 326 | $29,992 | $1,727 | 5.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 21 | 31 | $5,735 | $1,287 | 22.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 163 | 240 | $35,958 | $15,164 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 124 | $29,160 | $12,020 | 41.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 82 | 109 | $37,387 | $7,876 | 21.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 54 | 61 | $20,374 | $4,807 | 23.6% |
| 17000 | Destruction of skin growth | Office | 2021 | 88 | 122 | $24,644 | $4,799 | 19.5% |
About Dr. Lynn Cornelius, MD
Dr. Lynn Cornelius, MD is a Dermatology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922025451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lynn Cornelius, MD has received a total of $18,274 in payments from pharmaceutical and medical device companies, with $23.86 received in 2023. These payments were reported across 3 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($9,500).
As a Medicare-enrolled provider, Cornelius has provided services to 2,448 Medicare beneficiaries, totaling 3,866 services with total Medicare billing of $184,062. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Saint Louis, MO
- Active Since 07/17/2006
- Last Updated 04/17/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1922025451
Products in Payments
- TAFINLAR (Drug) $8,750
- BOTOX (Biological) $23.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Saint Louis
Elaine Siegfried, Md, MD
Dermatology — Payments: $1.1M
Dr. Craig Leonardi, M.d, M.D
Dermatology — Payments: $1.0M
Dr. Brian Kim, Md, MD
Dermatology — Payments: $760,788
Dr. Mary Noel George, Md, MD
Dermatology — Payments: $498,600
Dee Glaser
Dermatology — Payments: $241,089
Jeffrey Reed, Md, MD
Dermatology — Payments: $188,305